Luye Builds China Cancer Diagnosis Capability Via Vela Investment
This article was originally published in PharmAsia News
As a Chinese healthcare player investing money into the oncology treatment market, Luye Group is seeking to stay ahead of the competition by adding disease screening and in vitro diagnostics to its arsenal, via a major investment into Vela Diagnostics of Singapore. As the window of opportunity closes in, the two are working quickly to bring products to the China market.
You may also be interested in...
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.